SCHEMBL19564488

SCHEMBL19564488

CC(C)C(=O)c1ccccc1N1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.60
GAA P10253 6/20 0.49
L3MBTL1 Q9Y468 7/20 0.48
ATM Q13315 2/20 0.48
KCNQ2 O43526 2/20 0.48
MAPT P10636 5/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 3/20 0.46
EGFR P00533 1/20 0.46
RAF1 P04049 1/20 0.46
ALOX12 P18054 1/20 0.46
MAP2K1 Q02750 1/20 0.46
PTPN1 P18031 2/20 0.45
NPSR1 Q6W5P4 3/20 0.44
USP2 O75604 1/20 0.44
GLA P06280 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15372278 0.98 NPC1 (0.63) NPC1GAAL3MBTL1ATMKCNQ2
SCHEMBL15478265 0.80 NPC1 (0.66) NPC1GAAL3MBTL1ATMMAPT
SCHEMBL23708475 0.80 NPC1 (0.57) NPC1GAAL3MBTL1ATMKCNQ2
SCHEMBL28086833 0.80 NPC1 (0.70) NPC1GAAL3MBTL1ATMKCNQ2
SCHEMBL2492855 0.78 NPC1 (0.68) NPC1GAAL3MBTL1ATMALDH1A1
SCHEMBL29467270 0.78 NPC1 (0.68) NPC1GAAL3MBTL1ATMALDH1A1
SCHEMBL10676859 0.78 NPC1 (0.54) NPC1GAAL3MBTL1ATMKCNQ2
SCHEMBL5847089 0.78 GAA (0.58) NPC1GAAL3MBTL1ATMKCNQ2
Hydrochloric Acid SCHEMBL9851652 0.77 NPC1 (0.67) NPC1GAAL3MBTL1ATMMAPT
SCHEMBL31565663 0.77 NPC1 (0.96) NPC1GAAL3MBTL1ATMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938276-B2 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-04-10 US disclosed
US-9938276-B2 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-04-10 US disclosed
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY5R NPC1 1014/4885GAA 2579/4885L3MBTL1 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.